



EXPRESS MAIL LABEL #EL 253253925 US

06-28-05 JC04 Rec'd PCT/PTO 27 JUN 2005  
PC

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Matthew BAKER *et al.* )  
Application No. 10/517,707 )  
Filed: December 10, 2004 ) Group Art Unit: Unknown  
For: MODIFIED BRYODIN 1 WITH ) Attorney Docket No. MER-134  
REDUCED IMMUNOGENICITY )

SUPPLEMENTAL RESPONSE TO NOTIFICATION  
TO COMPLY WITH SEQUENCE REQUIREMENTS

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

This paper is in response to the Notification To Comply With Requirements For Patent Applications Containing Nucleotide and/or Amino Acid Sequence Disclosures, mailed May 18, 2005 for the above-identified application.


Please amend the application to enter the Substitute Sequence Listing submitted herewith in paper copy and Computer Readable Form.

SEQ ID NO: 7 in the Sequence Listing has been corrected to delete the erroneous inclusion of Xaa at position 1 in the sequence. The positions for the correct Xaa amino acids in SEQ ID NO: 7 have been adjusted accordingly. Support for the amendment is found in the specification at page 11, where the initial X<sup>0</sup> in SEQ ID NO: 7 is indicated to be a hydrogen or targeting moiety, not an amino acid. No new matter is added by this amendment.

Enclosed herewith is a copy of the Notice to comply with the sequence requirements.

Respectfully submitted,

Dated: 27 June 2005

By:   
Talivaldis Cepuritis (Reg. No. 20,818)

OLSON & HIERL, LTD.  
20 North Wacker Drive  
36th Floor  
Chicago, Illinois 60606  
(312) 580-1180



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
 United States Patent and Trademark Office  
 Address: COMMISSIONER FOR PATENTS  
 P.O. Box 1450  
 Alexandria, Virginia 22313-1450  
 www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/517,707	Matthew Baker	MER-134

INTERNATIONAL APPLICATION NO.
-------------------------------

PCT/EP03/06055

002387  
 OLSON & HIERL, LTD.  
 20 NORTH WACKER DRIVE  
 36TH FLOOR  
 CHICAGO, IL 60606

RECEIVED  
 MAY 31 2005  
 OLSON & HIERL, LTD.

IA. FILING DATE	PRIORITY DATE
06/10/2003	06/11/2002

CONFIRMATION NO. 4628

371 FORMALITIES LETTER



\*OC000000016049019\*

Date Mailed: 05/23/2005

## NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- The paper or compact disc copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e). Applicant must provide a substitute paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application OR a substitute computer readable form (CRF) copy of the "Sequence Listing". These two items must be the same. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patent Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patent Software Program Help @ [ebc@uspto.gov](mailto:ebc@uspto.gov)

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

VONDA M WALLACE

Telephone: (703) 308-9140 EXT 225

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/517,707	PCT/EP03/06055	MER-134

FORM PCT/DO/EO/922 (371 Formalities Notice)